drug activity T. To answer this question, which is increasingly important in the near future, some authors have developed new and different guidelines for the assessment of response. For GIST, Choi assessment on Ver Changes in tumor density as shown by computed tomography is based, and by the EORTC JNJ-38877605 Changes in carbohydrate metabolism determined as shown by positron emission tomography with FDG. No specific eligibility criteria are still for PET CT fusion techniques available, w While the new PET tracers for specific molecular pathways or metabolic portray be evaluated. As in clinical practice, we have completely still on the absence of morphological techniques or not Constantly validated functional techniques, the need to develop new criteria for assessing response is real, and this field of research is certainly in the n Next explode years.
MOLECULAR Specific treatments ITMN-191 and prognostic factors pr Represented predictive Despite the current revolution low by the addition of sorafenib to our arsenal at the moment and the m Resembled experimental treatments, remains HCC is an incurable disease, but it can be treated by the removal of radical surgery or transplantation . This lack of curative treatment options is the growing problem of cooperation of new molecular targeted agents, which is especially important t now that the financial resources are limited accompanied. These factors underscore the need for reliable Ssige prognostic and pr Predictive factors, another important line of research Conna T large e to recognize progress. Regarding sorafenib, we now know that the amount of ERK protein behind Ras in the MAP kinase pathway is correlated with PFS in patients treated with this drug. We must sorgf to identify and validate biomarkers validly and reliably to other k Providing more reliable Can patients who benefit ornot k can W choose, Co of these treatments Teux. This will allow us, the scarce resources to the most appropriate and pr Precise as m Possible to assign.
CONCLUSION treatment of specific target, although sometimes several molecular targets, has grown rapidly in oncology approach, most innovative and most powerful zukunftstr For the treatment of many solid tumors become. This approach looks very promising thanks to the development of HCC Sorafenib, the first medical treatment proven impact on the survival of HCC. Nevertheless, the results so far obtained are improved. We will pursue this goal by improving the definition and characterization of the molecular mechanisms of cancer development, and thus the development of specific, active and targeted molecular agents tolerated. Studies need Lokoregion us various means of this kind with one another and with herk Mmlicher chemotherapy or ablation or Re combine. New pr Diktiver and prognostic factors need to be identified, k Can be directly related to the moles